Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Safety Board Will Impact All "Medical Product" Activities, Crawford Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Commissioner plans to appeal to the House appropriations subcommittee for additional funding of agency programs.

You may also be interested in...



FDA Drug Safety Board To Meet Every Six Weeks

The board discussed FDA's recent action on fentanyl transdermal patches (J&J's Duragesic and generics) and Purdue's Palladone (hydromorphone extended-release) during a July 27 meeting, FDA's meeting summary says.

Drug Safety Oversight Board Proceedings Should Be More Open, Rep. DeLauro Says

FDA Commissioner Crawford defends the board as an "instrument of openness" in response to complaints that the panel's closed proceedings will fail to provide greater transparency.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel